Clavis Pharma ASA – Product Pipeline Review – 2012

Date: November 28, 2012
Pages: 99
Price:
US$ 1,500.00 US$ 1,350.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: C96D34291A8EN
Leaflet:

Download PDF Leaflet

Clavis Pharma ASA – Product Pipeline Review – 2012

SUMMARY

Global Market Direct’s pharmaceuticals report, “Clavis Pharma ASA - Product Pipeline Review - 2012” provides data on the Clavis Pharma ASA’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Clavis Pharma ASA’s corporate website, SEC filings, investor presentations and featured press releases, both from Clavis Pharma ASA and industry-specific third party sources, put together by Global Markets Direct’s team.

SCOPE
  • Clavis Pharma ASA - Brief Clavis Pharma ASA overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Clavis Pharma ASA human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Clavis Pharma ASA with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Clavis Pharma ASA’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
REASONS TO BUY
  • Evaluate Clavis Pharma ASA’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Clavis Pharma ASA in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Clavis Pharma ASA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Clavis Pharma ASA.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Clavis Pharma ASA and identify potential opportunities in those areas.
Clavis Pharma ASA Snapshot
Clavis Pharma ASA Overview
Key Information
Key Facts
Clavis Pharma ASA – Research and Development Overview
Key Therapeutic Areas
Clavis Pharma ASA – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Clavis Pharma ASA – Pipeline Products Glance
Clavis Pharma ASA – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Clavis Pharma ASA Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Clavis Pharma ASA – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Clavis Pharma ASA – Drug Profiles
azacitidine
Product Description
Mechanism of Action
R&D Progress
betamethasone
Product Description
Mechanism of Action
R&D Progress
budesonide
Product Description
Mechanism of Action
R&D Progress
CP-4055 + Idarubicin
Product Description
Mechanism of Action
R&D Progress
elacytarabine
Product Description
Mechanism of Action
R&D Progress
ganciclovir
Product Description
Mechanism of Action
R&D Progress
prednisolone
Product Description
Mechanism of Action
R&D Progress
Clavis Pharma ASA – Pipeline Products by Route of Administration
Clavis Pharma ASA – Pipeline Products By Mechanism of Action
Clavis Pharma ASA – Recent Pipeline Updates
Clavis Pharma ASA - Dormant Projects
Clavis Pharma ASA – Company Statement
Clavis Pharma ASA – Locations And Subsidiaries
Head Office
Clavis Pharma ASA, Recent Developments
Clavis Pharma ASA- Press Release
Jan 17, 2012: Clavis Pharma Provides Update On Phase III CLAVELA Trial For Treatment Of Acute Myeloid Leukemia
Dec 07, 2009: Clavis Pharma Presents Positive Phase II Clinical Study Results Of Elacytarabine At ASH Annual Meeting
Dec 07, 2009: Positive Phase II Clinical Data For Clavis Pharma's Elacytarabine Presented at ASH Annual Meeting
May 29, 2009: Clavis Pharma Presents Positive Clinical Data Of Elacytarabine At ASCO 2009
May 06, 2009: Clavis Pharma Announces Positive Preclinical Data For CP-4200
Apr 22, 2009: Clavis Presents Promising Clinical Results Of Elacytarabine Presented At AACR
Apr 22, 2009: Promising Elacytarabine Clinical Results Presented at AACR
Mar 16, 2009: Clavis Pharma Announces Positive Phase II Results Of Elacytarabine
Financial Deals Landscape
Clavis Pharma ASA, Deals Summary
Clavis Pharma ASA, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Skyline Diagnostics Enters Into Research Agreement With Clavis Pharma
Clavis Pharma Enters Into Collaboration Agreement With Mount Sinai School of Medicine
Licensing Agreements
Clavis Pharma Enters Into Licensing Agreement With Translational Therapeutics
Clavis Pharma Enters Into Licensing And Development Agreement With Clovis Oncology
Clavis Pharma Enteres Into Licensing Agreement With Ventana Medical Systems
Clavis Pharma Enters Into Licensing Agreement With Clovis Oncology
Equity Offering
Clavis Pharma Completes Private Placement Of Shares For $26.9 Million
Clavis Pharma Completes First Tranche Of Private Placement For $12 Million
Clavis Pharma Announces Private Placement For $3.5 Million
Clavis Pharma Completes Subsequent Offering Of $1.2 Million
Clavis Pharma Completes Private Placement Of $20 Million
Clavis Pharma Completes IPO Of $39 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Clavis Pharma ASA, Key Information
Clavis Pharma ASA, Key Facts
Clavis Pharma ASA – Pipeline by Indication, 2012
Clavis Pharma ASA – Pipeline by Stage of Development, 2012
Clavis Pharma ASA – Monotherapy Products in Pipeline, 2012
Clavis Pharma ASA – Combination Treatment Modalities in Pipeline, 2012
Clavis Pharma ASA – Phase III, 2012
Clavis Pharma ASA – Phase II, 2012
Clavis Pharma ASA – Pre-Clinical, 2012
Clavis Pharma ASA – Discovery, 2012
Clavis Pharma ASA – Pipeline By Route of Administration, 2012
Clavis Pharma ASA – Pipeline Products By Mechanism of Action, 2012
Clavis Pharma ASA – Recent Pipeline Updates, 2012
Clavis Pharma ASA - Dormant Developmental Projects,2012
Clavis Pharma ASA, Deals Summary
Skyline Diagnostics Enters Into Research Agreement With Clavis Pharma
Clavis Pharma Enters Into Collaboration Agreement With Mount Sinai School of Medicine
Clavis Pharma Enters Into Licensing Agreement With Translational Therapeutics
Clavis Pharma Enters Into Licensing And Development Agreement With Clovis Oncology
Clavis Pharma Enteres Into Licensing Agreement With Ventana Medical Systems
Clavis Pharma Enters Into Licensing Agreement With Clovis Oncology
Clavis Pharma Completes Private Placement Of Shares For $26.9 Million
Clavis Pharma Completes First Tranche Of Private Placement For $12 Million
Clavis Pharma Announces Private Placement For $3.5 Million
Clavis Pharma Completes Subsequent Offering Of $1.2 Million
Clavis Pharma Completes Private Placement Of $20 Million
Clavis Pharma Completes IPO Of $39 Million

LIST OF FIGURES

Clavis Pharma ASA – Pipeline by Indication, 2012
Clavis Pharma ASA – Pipeline by Stage of Development, 2012
Clavis Pharma ASA – Monotherapy Products in Pipeline, 2012
Clavis Pharma ASA – Combination Treatment Modalities in Pipeline, 2012
Clavis Pharma ASA – Pipeline By Route of Administration, 2012
Clavis Pharma ASA - Pipeline Products By Mechanism of Action, 2012

Ask Your Question

Clavis Pharma ASA – Product Pipeline Review – 2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: